Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€177.85

€177.85

-0.170%
-0.3
-0.170%
€282.11

€282.11

 
18.09.24 / Tradegate WKN: 789617 / Symbol: BIIB / Name: Biogen / Stock / Pharmaceuticals / Large Cap /
Latest predictions
€264.32
09.09.24
-1.90%
buy
€257.78
04.09.24
-4.36%
buy
€258.12
19.08.24
-3.94%
buy
€230.07
06.08.24
-2.71%
buy
€275.27
05.08.24
-2.28%
buy
€267.50
02.08.24
-5.62%
buy
Your prediction

Biogen Inc. Stock

Biogen Inc. shows a slight decrease today, losing -€0.300 (-0.170%) compared to yesterday.
The stock is one of the favorites of our community with 52 Buy predictions and 2 Sell predictions.
With a target price of 282 € there is a hugely positive potential of 58.56% for Biogen Inc. compared to the current price of 177.85 €.
So far the community has only identified positive things for Biogen Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Biogen Inc. in the next few years

Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Biogen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Biogen Inc. -0.170% -2.006% -2.622% -25.397% -24.385% -30.311% -17.339%
Johnson & Johnson -0.390% -0.948% 3.997% -0.661% 6.215% 7.107% 28.415%
Elanco Animal Health Inc. -1.330% -0.850% -1.597% 15.986% -3.402% -52.733% -
Pfizer Inc. -0.110% -0.408% 4.657% -15.947% 2.893% -28.214% -14.227%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-27

Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.

Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.

Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.

Comments

Prediction Buy
Perf. (%) -1.90%
Target price 264.318
Change
Ends at 09.09.25

Biogen Inc. (NASDAQ: BIIB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $292.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -4.36%
Target price 257.783
Change
Ends at 04.09.25

Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $285.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.94%
Target price 258.125
Change
Ends at 19.08.25

Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $285.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

News

A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.: https://g.foolcdn.com/editorial/images/785842/doctor-talking-to-a-patient-while-making-notes.jpg
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.

One thing that can help with the treatment of any disease is early detection, and Alzheimer's is no exception to that. And the good news is that in the near future, detecting cases of Alzheimer's

Biogen (BIIB) Q2 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Biogen (BIIB) Q2 2024 Earnings Call Transcript

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q2 2024 Earnings CallAug 01, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?: https://g.foolcdn.com/editorial/images/784901/gettyimages-1316264191.jpg
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?

Biogen (NASDAQ: BIIB) built itself into a multiple sclerosis (MS) treatment giant over the years -- but as older blockbusters lost exclusivity, growth stalled. And last year, annual revenue dropped